(August 11, 2016, 3:23 PM EDT) -- WASHINGTON, D.C. — The U.S. Supreme Court should not hear a petition to consider whether an appellate court’s interpretation of the Hatch-Waxman safe harbor, 35 U.S. Code Section 271(e)(1), is “overly narrow” and puts generic manufacturers at risk of patent suits, Momenta Pharmaceuticals Inc. argue in an Aug. 1 opposition brief (Amphastar Pharmaceuticals, Inc., et al. v. Momenta Pharmaceuticals, Inc. and Sandoz, Inc., No. 15-1402, U.S. Sup.).

(Respondents’ opposition brief available. Document #78-160815-005B.)

The Federal Circuit U.S. Court of Appeals ruled Nov. 10 that although a...